# Evidence Confirm Productionization RR-09 R1-R4 / R5a Plan Controller Judgment

Verdict token:

`ACCEPT_RR_09_R1_R4_R5A_RESIDUAL_PLAN_NOT_READY`

## Scope

Controller judgment for:

- Plan: `docs/reviews/evidence-confirm-productionization-rr-09-r1-r4-r5a-residual-plan-20260623.md`
- Initial plan review: `docs/reviews/plan-review-20260623-235818.md`
- Plan fix: `docs/reviews/evidence-confirm-productionization-rr-09-r1-r4-r5a-plan-fix-20260623.md`
- Targeted re-review: `docs/reviews/plan-review-20260623-235900.md`

No code change, live/PDF/provider/LLM execution, PR mutation, push, tag, release, or readiness claim is authorized by this judgment.

## Decision

Accept the fixed RR-09 R1-R4 / R5a residual plan.

The initial plan review found one material issue: the R1-R4 diagnostic goal could be read as allowing one representative sample to close all four R1-R4 residuals.

The plan fix resolves this by making R1-R4 evidence disposition sample-specific:

- a single-sample diagnostic may prove the method and classify only the diagnosed sample,
- unexamined samples remain open,
- closing or reclassifying all R1-R4 requires fact-level diagnostic coverage for all four RR-S2 failing samples, or an explicit table carrying unexamined samples open.

Targeted re-review concludes `pass-with-risks` with no material findings.

## Accepted Next Gate Options

The next controller may choose exactly one of these executable gates:

1. `RR-09 A1 R1-R4 Fact-level Diagnostic Authorization Gate`
   - Requires explicit user authorization before any repository-bounded live/PDF product diagnostic.
   - If only one sample is diagnosed, only that sample can be dispositioned.
2. `RR-09 B1 R5a Manager-strategy QDII Extraction/Anchor Implementation Gate`
   - Keeps `manager_strategy_text` mandatory P0 for QDII.
   - Must prove any change through extraction/anchor coverage, not quality-gate relaxation.
3. `RR-09 B2 R5a Manager-strategy QDII Product Applicability Decision Gate`
   - Product policy decision before any implementation.
   - Any later implementation must keep QDII gap semantics explicit.

Do not combine A1 live diagnostic with B1/B2 implementation unless the user explicitly authorizes that combined scope.

## Residuals

| Residual | Status | Owner / Next destination |
|---|---|---|
| R1-R4 EC `fail` under `warn` | open | Sample-specific fact-level diagnostic; live/PDF authorization required for product samples. |
| R5a `017641 / 2024` quality-gate block | open | `manager_strategy_text` QDII extraction/anchor gate or product applicability decision gate. |
| R5b blocked-path EC summary loss | closed | Branch F accepted; do not reopen without regression evidence. |
| Checklist Evidence Confirm support | deferred | Separate gate. |
| Report-body Evidence Confirm rendering | deferred | Separate gate. |
| Provider-backed semantic production default | deferred | Separate gate. |
| Tag/release/readiness | blocked | Separate release-boundary authorization and accepted readiness evidence. |

## Validation

Plan-only validation to run before commit:

```bash
git diff --check -- docs/reviews/evidence-confirm-productionization-rr-09-r1-r4-r5a-residual-plan-20260623.md docs/reviews/plan-review-20260623-235818.md docs/reviews/evidence-confirm-productionization-rr-09-r1-r4-r5a-plan-fix-20260623.md docs/reviews/plan-review-20260623-235900.md docs/reviews/evidence-confirm-productionization-rr-09-r1-r4-r5a-plan-controller-judgment-20260623.md docs/current-startup-packet.md docs/implementation-control.md
```

## Next Entry Point

`RR-09 A1 R1-R4 Fact-level Diagnostic Authorization Gate / RR-09 B1-B2 R5a Manager-strategy QDII Residual Gate`

Release/readiness remains `NOT_READY`.

Completion token:

`ACCEPT_RR_09_R1_R4_R5A_RESIDUAL_PLAN_NOT_READY`
